Angst, J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol. 1998; 13(Suppl 6): S1–S4.
Kennedy, SH, Rizvi, S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009; 29(2): 157–164.
Montejo, AL, Llorca, G, Izquierdo, JA, Rico-Villademoros, F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001; 62(Suppl 3): 10–21.
Clayton, AH, Pradko, JF, Croft, HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4): 357–366.
Serretti, A, Chiesa, A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009; 29(3): 259–266.
Williams, VS, Edin, HM, Hogue, SL, Fehnel, SE, Baldwin, DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010; 24(4): 489–496.
Baldwin, DS, Palazzo, MC, Masdrakis, VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat. 2013; 2013: 256841.
Reichenpfader, U, Gartlehner, G, Morgan, LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014; 37(1): 19–31.
Hu, XH, Bull, SA, Hunkeler, EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004; 65(7): 959–965.
Graf, H, Walter, M, Metzger, CD, Abler, B. Antidepressant-related sexual dysfunction—perspectives from neuroimaging. Pharmacol Biochem Behav. 2014; 121: 138–145.
Olivier, B, Chan, JS, Snoeren, EM, et al. Differences in sexual behaviour in male and female rodents: role of serotonin. Curr Top Behav Neurosci. 2011; 8: 15–36.
Fabre, LF, Clayton, AH, Smith, LC, Goldstein, I, Derogatis, LR. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. J Sex Med. 2012; 9(3): 821–829.
Keltner, NL, McAfee, KM, Taylor, CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care. 2002; 38(3): 111–116.
Bang-Andersen, B, Ruhland, T, Jorgensen, M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206–3221.
Oosting, RS, Chan, JSW, Pehrson, A, Li, Y, Sanchez, C, Olivier, B. P-42-016 Vortioxetine does not affect sexual behavior in a male rat model for sexual dysfunction [abstract]. Int J Neuropsychopharmacol. 2014; 17(S1): 138.
Katona, C, Katona, C. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014; 10: 349–354.
Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482–491.
Boulenger, J-P, Loft, H, Olsen, CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014; 29(3): 138–149.
Mahableshwarkar, A, Jacobsen, P, Chen, Y, Serenko, M, Trivedi, M. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015; 232(12): 2061–2070.
Mahableshwarkar, A, Jacobsen, P, Serenko, M, Chen, Y, Trivedi, M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5): 583–591.
Jacobsen, P, Mahableshwarkar, A, Serenko, M, Chan, S, Trivedi, M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5): 575–582.
Mahableshwarkar, AR, Jacobsen, PL, Chen, Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217–226.
Mahableshwarkar, AR, Jacobsen, PL, Chen, Y, Simon, JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract. 2014; 68(1): 49–59.
McGahuey, CA, Gelenberg, AJ, Laukes, CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000; 26(1): 25–40.
American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev.. Washington, DC: American Psychiatric Association; 2000.
Sánchez-Meca, J, Marín-Martínez, F. Meta-analysis of 2×2 tables: estimating a common risk difference. Educational and Psychological Measurement. 2001; 61(2): 249–276.
Landen, M, Hogberg, P, Thase, ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry. 2005; 66(1): 100–106.
Detke, MJ, Wiltse, CG, Mallinckrodt, CH, McNamara, RK, Demitrack, MA, Bitter, I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004; 14(6): 457–470.
Clayton, A, Kornstein, S, Prakash, A, Mallinckrodt, C, Wohlreich, M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007; 4(4 Pt 1): 917–929.